Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
10 new variants, even those vaccinated can get it again and it’s not even a low chance. Efficacy is not effectiveness. Glove demand will still be high until the effective actually reach 90% with adoption across every country which has trade. A good indicator is firstly India. Gloves won’t go up too a high but for now price too low!
Great company that’s vying on global markets going into green energy, poised to grow for the long term. Huge challenge at PE 90, but think company is poised for long term contract/gains
